Author archive for Admin Isofol

  • aside

    Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking…

    by
  • aside

    Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol…

    by
  • aside

    Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The…

    by
  • aside

    New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which…

    by
  • aside

    Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and…

    by
  • aside

    Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma…

    by
  • aside

    Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical…

    by
  • aside

    Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)…

    by
  • aside

    Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,…

    by
  • aside

    Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you…

    by